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Abstract
Protoporphyria is a disease characterized by a deficiency in ferrochelatase, the terminal enzyme in the heme biosynthetic
pathway, which catalyzes the chelation of iron and protoporphyrin to form heme. Clinical symptoms arise from an
accumulation of protoporphyrin behind the partial enzyme block and include photosensitivity and sometimes hepatobiliary
disease. Protoporphyria is described as an dominant disease, yet patients exhibit decreased ferrochelatase activities of 15^30%
of normal, not 50% as might be expected. Missense, nonsense, and splicing mutations have been identified in ferrochelatase
cDNA from protoporphyric patients. In this study we introduce an exon 10 deletion, an analogous mutation to that
described in some protoporphyric patients, into the mouse embryonic stem (ES) cell genome via homologous recombination.
Targeted ES cells were confirmed by Southern blot analysis. Expression of wild-type and exon 10-deleted mRNA was
demonstrated by reverse transcriptase^polymerase chain reaction (RT^PCR) and cDNA sequencing. Ferrochelatase levels
were analyzed by immunoblotting. Ferrochelatase activity was measured by the chelation of zinc and mesoporphyrin, and by
the decrease in protoporphyrin accumulation after adding N-aminolevulinic acid. In the exon 10+/3 ES cells there is
expression of both wild-type and exon 10-deleted mRNA, a 50% decrease in cross-reactive material with an anti-
ferrochelatase antibody, and an approximate 50% decrease in ferrochelatase activity compared to wild-type ES cells.
Therefore, an exon 10 deletion alone is insufficient to decrease ferrochelatase activity to the levels in protoporphyric patients.
This suggests the requirement of an additional mutation to decrease the expression of the wild-type allele. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Ferrochelatase is the ¢nal enzyme in the heme bio-
synthetic pathway and catalyzes the chelation of fer-
rous iron and protoporphyrin IX to form heme. The
human ferrochelatase gene consists of 11 exons
which span a region of approximately 40 kb on chro-
mosome 18q21 [1^3]. The ferrochelatase gene is ex-
pressed in all cells, which require its product, heme,
for essential proteins including the respiratory cyto-
chromes [4,5]. The highest level of ferrochelatase
gene expression is in erythroid cells to supply the
heme for hemoglobin [6,7].
Protoporphyria (PP) is an inherited disease that is
characterized enzymatically by a de¢ciency in ferro-
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chelatase activity and biochemically by increased
protoporphyrin levels. The clinical symptoms consist
of photosensitivity [8] and occasionally hepatobiliary
disease [9,10], which can progress to hepatic failure
and require liver transplantation [11]. The clinical
symptoms arise from the accumulation of the proto-
porphyrin, which is mainly produced during erythro-
poiesis [8,12].
Multiple defects in the ferrochelatase gene, which
include point mutations, nucleotide deletions, and a
partial chromosome deletion [13], have been iden-
ti¢ed in patients with protoporphyria. The point
mutations have resulted in frameshifts and stop co-
dons [14,15], amino acid substitutions [1,16,17], and
splicing defects [18^22]. Protoporphyria is generally
inherited as an autosomal dominant trait with vari-
able penetrance [23], with each patient or carrier hav-
ing one mutant ferrochelatase allele and one wild-
type (i.e., no detected mutation) allele. On the basis
of either having de¢cient enzymatic activity or of
carrying the identi¢ed mutation, one parent of each
patient has been identi¢ed as the carrier of the mu-
tant ferrochelatase allele and one parent as having
only wild-type alleles. Rare cases of protoporphyria
inherited as a recessive trait have been reported [24^
26].
The enzymatic activity of ferrochelatase in proto-
porphyric patients is usually reported at 15% to 30%
of normal, although a 50% reduction of enzymatic
activity would be expected in an autosomal domi-
nant disease with a null allele. Three hypotheses
have been suggested to explain this less-than-50%
activity. One hypothesis is that ferrochelatase is a
homodimer such that the mutant ferrochelatase acts
as a dominant negative protein to inhibit the wild-
type protein [1]. The functional size of ferrochelatase
is 82 kDa by radiation inactivation, which is consis-
tent with a functional ferrochelatase dimer [27]. A
second hypothesis is that the accumulated protopor-
phyrin acts to inhibit the enzymatic activity of the
active ferrochelatase thereby lowering its apparent
maximum velocity further. A third hypothesis is
that the ‘normal’ non-mutant ferrochelatase allele
in patients is expressed at a lower level so that the
ferrochelatase activity is less than 50% of normal
[23]. An A to G polymorphism at position 3251
kb (from the start codon) of the ferrochelatase pro-
moter has been identi¢ed in some patients with pro-
toporphyria [28]. The functional signi¢cance of this
polymorphism is unknown, and it is not localized to
any of the cis-acting elements identi¢ed in the pro-
moter [5].
Two animal models have been described for pro-
toporphyria. A natural occurring mutation in cattle
requires a homozygous recessive genotype for pheno-
typic expression [29,30]. Secondly, a mouse mutagen-
ized with EMU (ethylnitrosourea) [31], has been de-
scribed that contains a T to A transversion at
nucleotide 293 [32]. This mutation must exist in a
homozygous state to result in a protoporphyric phe-
notype. Neither of these animal models provides a
paradigm of genetic heritability that is similar to that
described for dominantly transmitted human proto-
porphyria.
The extensive sequence data on the ferrochelatase
gene that has been generated from protoporphyric
patients has led to testable hypotheses on the molec-
ular pathogenesis of this disease. In the present study
we have introduced an exon 10 deletion into one
ferrochelatase allele by targeting the genome of
mouse embryonic stem (ES) cells. This exon 10 dele-
tion is functionally analogous to the exon 10 deletion
in ferrochelatase mRNA which has been described
for several individuals and families with protopor-
phyria [19,28]. Exon 10 of ferrochelatase in human
and mouse are highly conserved with only a single
amino acid change; valine 362 in human [33] is ala-
nine 361 in mouse [4]. When exon 10-deleted human
ferrochelatase is expressed in bacteria, the mutant
ferrochelatase has no enzymatic activity [34]. The
absence of amino acids conferred by exon 10 is
thought to disrupt the 2 iron/2 sulfur cluster which
is located in the carboxyl terminus and required for
ferrochelatase activity [34,35].
If the resultant mutant ferrochelatase protein acts
in a dominant negative manner, or if the accumu-
lated protoporphyrin inhibits the enzymatic activity
of the wild-type ferrochelatase protein, then we pre-
dict the exon 10+/3 mutant cell will have a ferroche-
latase activity less than 50% of normal. If the func-
tion of the wild-type allele is una¡ected by the
mutant allele, then we predict a ferrochelatase activ-
ity of 50% of normal, which is consistent with the
requirement of an additional mutation to further re-
duce the ferrochelatase activity in patients with pro-
toporphyria.
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2. Materials and methods
2.1. Targeting vector
The parental targeting vector, OSDUPDEL, con-
tains the neomycin resistance marker for positive se-
lection and the thymidine kinase marker for negative
selection. The targeting vector arms derived from
regions £anking exon 10 of the mouse ferrochelatase
gene were isolated from a cosmid clone containing
exons 3^11. The cosmid clone, 2719, was digested
with restriction endonucleases and mapped by South-
ern blot using a 32P-labeled oligo probe speci¢c for
the mouse ferrochelatase exon 10. The sequence for
the exon-speci¢c probe was deduced from the human
intron/exon boundaries. A 10 kb EcoRI fragment
containing part of intron 8, and exon 9 to 11 was
identi¢ed, subcloned (clone RID) into pBluescript
SK+ (Stratagene, San Diego, CA), and further ana-
lyzed by automated sequencing. To preserve the cis-
elements required for mRNA splicing, we identi¢ed
two DNA fragments that contained intact splice do-
nor and acceptor sites which would allow exon 9 to
be spliced to exon 11. A 4.5 kb AlwNI fragment
containing part of intron 8, exon 9 and part of intron
9, and a 1.8 kb BamHI fragment containing part of
intron 10 and exon 11 was isolated from the RID
clone. The ends of both fragments were blunted with
Klenow using standard methods [36]. The 6.1 kb
fragment was inserted into the PmlI site, and the
1.8 kb fragment was inserted into the HpaI site of
OSDUPDEL. Orientation of the mouse ferrochela-
tase gene inserts were assessed by restriction endonu-
clease analysis and automated sequencing.
2.2. Cell culture and targeting selection
The ES cell clone (BK4), a subclone of E14TG2a,
was used for targeting the mouse ferrochelatase gene
[37]. The cell line was derived from a 129/Ola mouse
strain. ES cells were maintained on irradiated mouse
embryonic ¢broblasts in DMEM-H, 15% fetal bo-
vine serum (Gibco/BRL, ES quali¢ed), 0.1 mM L-
mercaptoethanol, and 2 mM L-glutamine. Approxi-
mately 2U107 ES cells were electroporated with 15
Wg of the mouse ferrochelatase targeting vector line-
arized with PmeI restriction endonuclease. The cells
were suspended in 0.5 ml of phosphate-bu¡ered sal-
ine (PBS) with the DNA and pulsed in a 4-mm gap
electroporation cuvette with 350 V, 50 WF for 1 s.
Cells were immediately transferred to a 10-cm plate
containing G418-resistant, irradiated embryonic ¢-
broblasts in the growth media previously described.
After 24 h, the growth medium was supplemented
with 200 Wg/ml geneticin (Gibco/BRL, Gaithersburg,
MD) and 50 Wg/ml ganciclovir. Following 10 days of
selection, clonal populations were isolated, expanded
and analyzed for proper targeting by Southern blot.
After selection, undi¡erentiated wild-type and
MFC10+/3 ES cells were maintained in growth me-
dium supplemented with 4 U/ml rLIF (recombinant
leukemia inhibiting factor, Gibco/BRL). To initiate
primary di¡erentiation, ES cells were trypsinized,
washed twice with PBS, then 1.5U105 cells were
plated in bacterial grade petri dishes containing Isco-
ve’s media supplemented with 15% fetal calf serum
(Hyclone, Logan, UT), 1% glutamine 0.2% mono-
thioglutamate (MTG), 50 Wg/ml ascorbic acid, 200
Wg/ml iron saturated human transferrin and 5% pro-
tein-free hybridoma media II (PFHMII, Gibco/
BRL). Di¡erentiation cultures were maintained in a
humidi¢ed atmosphere containing 5% CO2 at 37‡C
for 4 days.
2.3. Southern blot analysis and RT^PCR
Individual G418 resistant/ganciclovir sensitive col-
onies were analyzed for correct targeting by South-
ern blotting [36]. Genomic DNA was isolated by
standard methods [38], digested with EcoRI restric-
tion endonuclease, separated on a 0.7% agarose Tris-
acetate^EDTA (TAE) gel, transferred to Magna-
graph membrane (MSI, Westboro, MA), and UV
crosslinked. The blot was probed with an exon 11-
speci¢c 32P-labeled random primed probe, which
would distinguish between homologous recombina-
tion or random integration. After 12 h of hybridiza-
tion in Rapid-Hyb bu¡er (Amersham, Arlington
Heights, IL) containing 106 cpm/ml of probe, the
blot was washed once in 5USSC/0.1%SDS at 55‡C,
once in 0.1USSC/0.1% SDS at 55‡C, twice in
0.1USSC/0.1% SDS at 60‡C, and then exposed to
¢lm (XOMAT-AR, Kodak, Rochester, NY) for
48 h at 380‡C with intensifying screens.
RT^PCR was used to analyze the spliced RNA
transcript from the targeted allele. Trizol reagent
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(Gibco/BRL) was used to isolate total RNA from ES
clones that had been separated from embryonic ¢-
broblast feeder cells by passaging 3^4 times in
feeder-cell free tissue culture dishes. The culture
dishes were treated with 0.1% gelatin in PBS prior
to the addition of growth medium and cells. One Wg
of total RNA was added to a standard RT reaction
[36], then 1/5 of the RT reaction (about 120 ng of
template) was used for PCR ampli¢cation using a
primer set that ampli¢ed a 340 bp region from
exon 8 (PR1: 5P-CCG ACT GGT TTG GCA GTC
CA-3P) to exon 11 (PR2: 5P-GAA GGA TTT AGT
CTT CCT GCA-3P). Temperatures were cycled 30
times at 94‡C for 15 s, 58‡C for 15 s, and 72‡C for
45 s. Ampli¢cation products were analyzed on a 4%
TBE^acrylamide gel stained with ethidium bromide.
2.4. Ferrochelatase immunoblot
To assess the ferrochelatase levels in targeted cells,
undi¡erentiated (feeder-cell free) wild-type and
MFC10+/3 ES cells were lysed in RIPA bu¡er
(0.15M NaCl, 50 mM Tris^HCl (pH 7.2), 1% deox-
ycholic acid, 1% Triton-X 100, 0.1% SDS) contain-
ing 10 Wg/ml PMSF. 15 Wg of whole cell lysate was
separated on a 10% SDS^polyacrylamide gel and
electrophoretically transferred to nitrocellulose.
Equal loading of protein was assessed by Ponceau
S staining. The membrane was then blocked with
BLOTTO (5% w/v non-fat dried milk in water) for
15 min at room temperature. Then, a 1:500 dilution
in BLOTTO of anti-recombinant human ferrochela-
tase polyclonal antibody [39] was applied to the blot
and allowed to incubate at room temperature for 4 h.
The blot was then washed once with BLOTTO
and twice in TBS^Tween (Tris-bu¡ered saline con-
taining 0.1% Tween-20). A goat anti-rabbit alkaline
phosphatase conjugated secondary antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA) was then
applied at a 1:1000 dilution in BLOTTO and al-
lowed to incubate for 1 h at room temperature.
The membrane was washed once in TBS^Tween,
once in BLOTTO and twice in TBS^Tween for 10
min each at room temperature. Western Blue sub-
strate (Promega, Madison, WI) was added and the
immunoblot was allowed to develop for approxi-
mately 20 min.
2.5. N-Aminolevulinic acid assay
The N-aminolevulinic acid (ALA) assay to indi-
rectly assess ferrochelatase activity was performed
as previously described [39,40]. Wild-type and
MFC10+/3 ES cells were plated into 6-well cluster
35-mm tissue culture dishes and allowed to grow to
con£uency. Cells were washed twice with PBS, and
2.0 ml of fresh DMEM-H growth media (without
serum) was added that contained 50 WM FeSO4
and 0, 50, 100, 250, 500 or 750 WM ALA (Porphyrin
Products, Logan, UT). Cells were incubated in a hu-
midi¢ed atmosphere containing 5% CO2 at 37‡C for
16, 20 and 24 h. After incubation in ALA, the cells
were washed once with PBS, and 750 Wl of 1:1 (v/v)
0.1 N perchloric acid/methanol solution was added
to extract the protoporphyrin. The samples were
£uorometrically analyzed for protoporphyrin with
protoporphyrin standards (Porphyrin Products)
using a Perkin^Elmer LS-50B spectro£uorimeter
(excitation: 406 nm; emission: 605 nm).
2.6. Ferrochelatase activity assays
The zinc^protoporphyrin assay was performed es-
sentially as described [39,41]. Approximately 1U107
undi¡erentiated ES cells or embryoid bodies from a
4-day di¡erentiation culture were lysed in palmitic
acid bu¡er (0.25 M Tris^HCl (pH 7.4), 1.75 mM
palmitic acid, 1% (v/v) Tween-20) containing 10
Wg/ml PMSF. Lysates were sonicated twice in a
Branson sonicator for 10 s and incubated on ice.
The enzymatic chelation of zinc and protoporphyrin
was carried out in a reaction that contained 500 Wg
of whole cell lysate, 100 WM zinc acetate, and 100
WM protoporphyrin in palmitic acid bu¡er. The
reaction was incubated at 37‡C in the dark. After
30 min, 0.5 ml of ice-cold 8:2 methanol/DMSO
(dimethyl sulfoxide) was added to stop the reaction.
The protein was pelleted before loading the HPLC
column by spinning for 10 min at 12 000Ug. To
detect the zinc^protoporphyrin product, 200 Wl of
the reaction was applied to a Delta Pak, 5 Wm,
C18 300 Aî , HPLC column (Waters, Milford, MA)
and separated in an 88% methanol, 12% 1 M am-
monium actetate (pH 5.16) mobile phase with a 1.5
ml/min £ow rate. The column £ow-through was
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directed into the £ow cell adapter of the spectro-
£uorimeter, which was set to an excitation wave-
length of 410 nm and an emission wavelength of
590 nm. Concentrations of zinc^protoporphyrin
were determined by comparing samples to a standard
curve derived from zinc^protoporphyrin (Porphyrin
Products).
2.7. Ferrochelatase kinetics
The zinc^mesoporphyrin assay was performed es-
sentially as described [42]. Undi¡erentiated ES cells
were grown to con£uency, and washed twice with
PBS. Four 10-cm plates were lysed in 250 Wl ice-
cold sucrose bu¡er (10 mM Tris-acetate (pH 8.1),
0.25 M sucrose) and freeze-thawed twice. Lysate pro-
tein concentrations were determined using BioRad
Protein Assay reagent. Then, 200 Wg of total cell
lysate was added to each reaction containing palmitic
acid bu¡er and the appropriate amounts of zinc and
mesoporphyrin. To determine the Km and Vmax for
ferrochelatase, mesoporphyrin IX (Porphyrin Prod-
ucts, Logan, UT) was varied to ¢nal concentrations
of 40 WM, 20 WM, 10 WM, 6.7 WM, or 5 WM with a
constant zinc acetate concentration of 200 WM. The
zinc acetate was also varied with ¢nal concentrations
of 40 WM, 20 WM, 10 WM, 6.7 WM, or 5 WM with a
constant mesoporphyrin IX concentration of 40 WM.
The reaction was allowed to proceed for 30 min at
37‡C in the dark and was stopped by the addition of
ice-cold 30% DMSO/70% methanol. Before loading
the reaction product on the HPLC column, the pro-
tein was pelleted at 12 000Ug for 10 min. To detect
the Zn-mesoporphyrin reaction product, 200 Wl of
the reaction was loaded onto an ODS-Hypersil,
5 Wm, 250 mmU4 mm reverse phase column (Hew-
lett^Packard, Wilmington, DE) and separated in an
88% methanol, 12% 1 M ammonium actetate (pH
5.16) mobile phase with a 1.25 ml/min £ow rate.
The column £ow-through was directed into the
£ow cell adapter of the spectro£uorimeter, which
was set to an excitation wavelength of 403 nm and
an emission wavelength of 574 nm. Concentrations
of zinc^mesoporphyrin were determined by compar-
ing samples to a standard curve derived from zinc^
mesoporphyrin (Porphyrin Products).
3. Results
3.1. Targeting the mouse ferrochelatase gene
A cosmid clone containing exon 3 to exon 11 of
the mouse ferrochelatase gene was mapped by re-
striction endonuclease analysis, Southern blot analy-
sis and automated DNA sequencing. A 10 kb EcoRI
fragment of the 3P end of the ferrochelatase gene,
which contained part of intron 8 and exon 9 to
exon 11, was subcloned into pBluescript SK+ (Stra-
tagene, San Diego, CA). To introduce an exon 10
deletion into the mouse ferrochelatase gene, two
fragments, neither containing exon 10, were cloned
£anking the neomycin resistance gene marker. One
fragment contained part of intron 8, exon 9 and part
of intron 9, and the second fragment contained part
of intron 10 and part of exon 11 (Fig. 1). This com-
bination of ferrochelatase gene fragments preserves
the splice donor site for exon 9 and the acceptor
site for exon 11. The product of a homologous re-
combination between the targeting vector and the
ferrochelatase gene would produce a ferrochelatase
allele that would lack exon 10, but contain all splice
donor and acceptor sites for the correct splicing of
exon 9 to exon 11 in the mRNA.
The linearized ferrochelatase targeting vector was
electroporated into ES cells derived from the 129/Ola
mouse strain. The ES cells were positively selected
for homologous recombination and negatively se-
lected for random integration for 10 days. Individual
clones were isolated and expanded, and Southern
blot analysis was used to analyze the ES clones for
proper targeting of the ferrochelatase gene (Fig. 2).
The exon 11-speci¢c probe used in the analysis dis-
tinguishes between a random integration event and a
homologous recombination event. The targeting ra-
tio for this locus was one homologous recombination
to four random integrations.
3.2. The targeted allele produces an exon 10-deleted
ferrochelatase mRNA
To determine if the targeted allele was producing
ferrochelatase mRNA that resulted from the splicing
of exon 9 to 11, we isolated total mRNA from wild-
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type and MFC10+/3 ES cells (grown in the absence
of ¢broblast feeders) and analyzed the populations of
ferrochelatase mRNA by RT^PCR. The presence of
the splice donor site for exon 9 and splice acceptor
site for exon 11 should result in the splicing out of
the neomycin resistance gene and the joining of exon
9 to 11 to produce an inframe ferrochelatase mRNA
without exon 10. RT^PCR analysis of MFC10+/3
RNA shows a 340 bp PCR fragment corresponding
to the size of the wild-type cDNA and a smaller
fragment which corresponds to the exon 10-deleted
cDNA (Fig. 3B). A third PCR fragment appears in
the RT^PCR ampli¢cation of the MFC10+/3 RNA
(Fig. 3B). The slowest migrating fragment was larger
than the wild-type cDNA fragment and was initially
thought to contain the neomycin resistance gene
cDNA. However, when this band was excised from
the gel and re-ampli¢ed by PCR, two smaller bands
appeared in equivalent quantities that corresponded
to the sizes of the wild-type and the exon 10-deleted
cDNAs. This suggests that the large PCR fragment is
a heteroduplex consisting of a wild-type strand and
an exon 10-deleted strand. Mixing equimolar quanti-
ties of wild-type and exon 10-deleted single stranded
fragments produced a heteroduplex fragment with an
equivalent size to that observed in the RT^PCR (not
shown). The greater intensity of the wild-type PCR
band compared to the exon 10-deleted band was ob-
served in three separate experiments.
To con¢rm the exon 10-deleted allele was produc-
ing an inframe mRNA in which exon 9 was joined to
exon 11, the wild-type and exon 10-deleted PCR
Fig. 1. Targeting the mouse ferrochelatase gene. (A) Schematic of the mouse ferrochelatase locus. Intron regions are represented by
lines, exon regions are noted by open boxes. (B) Targeting vector used to introduce an exon 10 deletion into the mouse ferrochelatase
gene. The neomycin resistance gene and thymidine kinase gene, and their direction of transcription, are represented by arrowed boxes.
(C) The product of a homologous recombination event results in the deletion of exon 10 in the mouse genome. Restriction endonu-
clease sites are noted: A, AlwN;, B, BamHI; E, EcoRI.
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fragments were cloned into pPCR II (Invitrogen,
Carlsbad, CA) and then analyzed by automated se-
quencing. The DNA sequence obtained con¢rms that
the PCR fragment ampli¢ed from the exon 10-de-
leted mRNA lacks exon 10 and shows exon 9 se-
quence adjacent to exon 11 sequence. Translation
of this mutant mRNA transcript produces an in-
frame ferrochelatase product that lacks the amino
acids encoded by exon 10 (Fig. 3C).
3.3. Accumulation of protoporphyrin in situ is 50% to
60% higher in MFC10+/3 cells compared to
wild-type cells
To observe the biochemical manifestation of the
exon 10 deletion, we measured the accumulation of
protoporphyrin from MFC10+/3 and wild-type cells
treated with N-aminolevulinic acid (N-ALA), the
product of the ¢rst and rate-limiting enzyme in the
heme biosynthetic pathway, N-ALA synthase. When
N-ALA is added exogenously to cells, it is quickly
converted to protoporphyrin by several downstream
enzymes, and high levels of protoporphyrin accumu-
late behind ferrochelatase. As the protoporphyrin is
converted to heme, the level of protoporphyrin
(measured by £uorescent emission) decreases and
provides an indirect measurement of ferrochelatase
activity. After treating MFC10+/3 or wild-type cells
with N-ALA (from 50 WM to 750 WM), we observed
an approximately 50% to 60% higher accumulation
of protoporphyrin in MFC10+/3 cells compared to
wild-type cells (Fig. 4).
3.4. Ferrochelatase levels and activities in MFC10+/3
ES cells are 50% of the wild-type, with a similar
Km for zinc and mesoporphyrin IX
We next analyzed whole cell extracts for ferroche-
latase protein using an anti-human ferrochelatase
polyclonal antibody that cross-reacts with mouse fer-
rochelatase. Immunoblot analysis of undi¡erentiated
wild-type and MFC10+/3 ES cells con¢rms that
there is approximately 50% less wild-type ferrochela-
tase in the MFC10+/3 extracts compared to the
wild-type extracts (Fig. 5A). We observed no cross-
reactive material that would correspond to the size of
an exon 10-deleted ferrochelatase.
The activity of ferrochelatase in wild-type and
Fig. 2. Southern blot analysis of targeted ES cells. After clonal expansion of geneticin-resistant, ganciclovir-sensitive cells, genomic
DNA was isolated, digested with EcoRI and analyzed by Southern blot using an exon 11-speci¢c DNA probe (hatched box). T.C.
represents the targeting construct, WT represents the parental cell line, and MT(1) and MT(2) represent two individual targeted
clones. The schematic to the right of the gel represents the region of each fragment (gray lines) detected by the probe.
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MFC10+/3 cells was determined by measuring the
chelation of ionic zinc and protoporphyrin to make a
zinc^protoporphyrin product, which was detected us-
ing a sensitive £uorometric assay. Although zinc is
not the primary substrate for ferrochelatase in vivo,
it is an e¡ective substrate in vitro [42,43]. We as-
sessed the ferrochelatase activity in undi¡erentiated
and 4-day di¡erentiated embryoid bodies of wild-
type and MFC10+/3 cells. The ferrochelatase activ-
ity in the MFC10+/3 cells is 40% to 50% lower than
in the wild-type cells in both undi¡erentiated and
4-day di¡erentiated embryoid bodies (Fig. 5B).
Fig. 3. Expression of the targeted allele. (A) The location of the primers (Pr1 and Pr2) and the region of ferrochelatase mRNA ampli-
¢ed in the RT^PCR reaction. (B) RT^PCR reaction products were separated by PAGE and stained with ethidium bromide for visual-
ization. Schematic to the right of the gel indicates the exon status of the products ampli¢ed from the mRNA. +10 contains exon 10,
310 does not contain exon 10. HD represents the heteroduplex that results from the annealing of an exon 10+ and 103 DNA strand.
(C) To further con¢rm the exon 10 status of the PCR bands, +10 and 310 PCR products were cloned and sequenced. The 310 PCR
fragment did not contain the sequence for exon 10 (translated sequence in gray), but proved to maintain the proper reading frame for
amino acids conferred by exon 9 and exon 11, as demonstrated by the lysine from exon 9 (black) being adjacent to the alanine from
exon 11 (black).
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To determine if the mutant ferrochelatase was ex-
erting a dominant negative e¡ect on the wild-type
ferrochelatase, we assessed the a⁄nity of ferrochela-
tase for its substrates. We conducted kinetics assays
using ferrochelatase activities from whole cell ex-
tracts and mesoporphyrin IX as the porphyrin sub-
strate for ferrochelatase, which results in higher assay
sensitivity compared to the native protoporphyrin
substrate [42]. Zinc was used as the metal substrate
to allow for the £uorescent detection of the zinc^
mesoporphyrin product. Lineweaver^Burk analysis
was used to determine the Km for the zinc and
mesoporphyrin substrates and apparent maximal ve-
locity of the enzyme. Although the maximal velocity
for ferrochelatase in the MFC10+/3 cells was
48% þ 5% that of wild-type cells, the Km for meso-
porphyrin IX and zinc were similar in both wild-
type and mutant cells (Km mesoporphyrin IX:
WT = 4.18 þ 0.60 WM; MFC10+/3= 4.52 þ 0.48
WM; Km zinc: WT = 11.8 þ 1.3 WM; MFC10+/3=
16.5 þ 1.6 WM) (Fig. 6).
4. Discussion
Protoporphyria is generally described as an auto-
somal dominant disorder with variable penetrance
[23]. Although one would expect that a genetic com-
position consisting of a normal allele and a null allele
for ferrochelatase would result in a 50% decrease in
ferrochelatase activity, the activity in protoporphyric
patients is consistently only 15% to 30% of normal
[9,44,45]. We have introduced an exon 10 deletion, a
well described mutation identi¢ed in human proto-
porphyria, into the mouse ferrochelatase gene by ho-
mologous recombination to assess the e¡ect of this
single mutation on ferrochelatase in undi¡erentiated
and di¡erentiated embryonic stem cells. This study
provides new insights into the molecular pathogene-
sis of protoporphyria.
After targeting the mouse ferrochelatase locus, we
assessed the expression from the wild-type and mu-
tated ferrochelatase alleles by RT^PCR analysis, and
Western blotting. Using RT^PCR analysis, both
wild-type and exon 10-deleted ferrochelatase mRNAs
Fig. 4. Increased accumulation of protoporphyrin in MFC10+/
3 cells. N-ALA was added to undi¡erentiated WT and MT
(MFC10+/3) ES cells at concentrations that ranged from 50
WM to 750 WM. After 16 h, protoporphyrin was extracted from
the cells and analyzed by spectro£uorimetry. Protoporphyrin
accumulation is represented as pmol protoporphyrin produced
per Wg total protein per 16 h. Additional time-course experi-
ments at 20 h and 24 h yielded equivalent results.
Fig. 5. Ferrochelatase levels and activity in MFC10+/3 cells.
(A) Fifteen Wg of whole cell extracts from undi¡erentiated WT
and MT (MFC10+/3) ES cells were separated by SDS^PAGE
and stained with an anti-recombinant human ferrochelatase
antibody with subsequent visualization using an alkaline phos-
phatase conjugated secondary antibody and Western Blue sub-
strate. (B) Ferrochelatase activity from WT and MT cells was
assessed by measuring the chelation of zinc and protoporphyr-
in. The concentration of the zinc^protoporphyrin product was
analyzed by HPLC separation and spectro£uorometric detec-
tion. White bars represent ferrochelatase activities from undif-
ferentiated ES cells (maintained in rLIF), and black bars repre-
sent 4-day di¡erentiated embryoid bodies (EB).
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from the targeted cells were observed. In three sepa-
rate experiments using semi-quantitative conditions,
the mutant mRNA was expressed at a lower level
than that of the wild-type mRNA (Fig. 3B). A recent
report assessed ferrochelatase expression from the
wild-type allele and the exon 10-deleted allele in a
family with protoporphyria [28]. Quantitation of al-
lele speci¢c ferrochelatase expression showed that the
exon 10-deleted mRNA levels were less than the
wild-type mRNA levels. This decreased mutant fer-
rochelatase mRNA level may re£ect decreased tran-
scription of the mutant allele or decreased mRNA
stability. Restriction mapping of the ferrochelatase
gene shows that the locus is heterogeneous [46]. Per-
haps these genetic di¡erences confer cryptic splice
sites which lead to aberrant splicing and instability
of the ferrochelatase mRNA. Additionally, studies in
other systems have shown that mutations in splicing
consensus sites lead to unstable mRNA. For exam-
ple, a four-base insertion in the coding region of the
HEXA gene, which is responsible for Tay^Sachs dis-
ease, results in a frameshift and a less stable mRNA
[47].
An immunoblot of extracts from exon 10-deleted
ES cells using a polyclonal anti-ferrochelatase anti-
body con¢rmed approximately 50% less cross-reac-
tive material at 42 kDa compared to extracts from
wild-type ES cell (Fig. 5A); however, there was no
cross-reactive material observed that corresponded to
the size of an exon 10-de¢cient protein. We and
others have analyzed whole cell and mitochondrial
extracts from protoporphyric patients with con¢rmed
exon deletions and have been unable to detect any
cross-reactive material that would correspond to
exon-deleted ferrochelatases [48]. Although we can-
not rule out that the polyclonal antibody may not
recognize epitopes on the mutant protein, it is more
likely that the decreased stability of the mutant
mRNA results in less mutant protein which is unde-
tectable using immunostaining methods. Alterna-
tively, it may be a combination of the instability of
both the mutant mRNA and mutant protein that
results in the inability to detect the exon 10-deleted
ferrochelatase.
Although ferrochelatase activities in protoporphy-
ric patients are 15% to 30% of normal, we observed
higher ferrochelatase activities of 40% to 50% of nor-
mal in both undi¡erentiated and di¡erentiated exon
10+/3 cells. However, there was no di¡erence in fer-
rochelatase activities in undi¡erentiated or 4-day dif-
ferentiated embryoid bodies, which contain various
non-erythroid cells and early erythroid precursors. It
may be that ferrochelatase is not expressed at higher
levels until later in development, or that there were
too few erythroid cells expressing high levels of fer-
Fig. 6. Kinetic analysis of ferrochelatase from WT or MFC10+/3
cells. To determine the Vmax and Km for ferrochelatase, (A)
mesoporphyrin was varied to a ¢nal concentration of 40 WM,
20 WM, 10 WM, 6.7 WM, or 5 WM with a constant zinc concen-
tration of 200 WM, or (B) the zinc was varied to ¢nal concen-
trations of 40 WM, 20 WM, 10 WM, 6.7 WM or 5 WM with a
constant mesoporphyrin concentration of 40 WM. The zinc^mes-
oporphyrin product was separated by HPLC and the concentra-
tion subsequently analyzed by spectro£uorimetry. The Vmax for
ferrochelatase in the MFC10+/3 cells (MT) was 48% þ 5% of
the wild-type (WT) cells. The Kms for mesoporphyrin were an
average of 4.18 WM (WT) and 4.52 WM (MT), and the average
Kms for zinc were 11.8 WM (WT) and 16.5 WM (MT). The data
represent average velocities and Km values from three separate
experiments.
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rochelatase to contribute to an observable increase in
activity. Nevertheless, there was a consistent 50^60%
decrease in activity observed in undi¡erentiated and
di¡erentiated MFC10+/3 cells.
The biochemical manifestation of protoporphyria
is the accumulation of protoporphyrin IX. To indi-
rectly measure the ferrochelatase activity in situ, we
induced high levels of protoporphyrin production
in undi¡erentiated ES cells by treating cells with
N-ALA, an upstream precursor of protoporphyrin.
In the presence of ferrous iron, the protoporphyrin
is converted to heme by ferrochelatase and the intra-
cellular levels of protoporphyrin decrease. The ob-
served ferrochelatase activities in the MFC10+/3 re-
sulted in the accumulation of 50% to 60% more
protoporphyrin compared to wild-type cells. These
activity levels are consistent with the in vitro meas-
urements of ferrochelatase activities.
Because ferrochelatase functions as an integral
membrane protein, it is conceivable that disruption
of membrane composition may a¡ect the activity of
the enzyme. Perhaps during erythropoiesis when high
levels of lipid soluble protoporphyrin are produced, a
protoporphyric cell may accumulate excessive proto-
porphyrin, which may disrupt the mechanics of the
mitochondrial membrane thus decreasing the ferro-
chelatase activity below 50%. Data from the N-ALA
assay supports this concept by demonstrating a de-
crease in ferrochelatase activity to 40% to 50% of
normal. However, this activity is still greater than
the 10% to 27% activity of normal which is observed
in ¢broblasts from protoporphyric patients using an
identical assay [39].
To further examine the possibility that the mutant
ferrochelatase may be interacting with the wild-type
ferrochelatase to exert a dominant negative e¡ect, we
conducted Michaelis^Menten kinetics using extracts
from wild-type and MFC10+/3 cells. We predicted
that if the mutant ferrochelatase was interacting with
the wild-type ferrochelatase to disrupt its catalytic
activity, then we would observe a Vmax value of
less than 50% in the mutant extracts and an apparent
Km value indicating competitive inhibition. If there
was no productive interaction between the two spe-
cies of ferrochelatase, we would observe a Vmax of
50% and no change in the apparent Km. Our data
show that there is a 48% þ 5% decrease in maxi-
mal velocity for ferrochelatase in MFC10+/3 ex-
tracts. The apparent Km values for zinc and meso-
porphyrin are nearly identical for both wild-type and
MFC10+/3 ferrochelatase, thus corroborating the
notion that there is 50% less functional ferrochelatase
in the MFC10+/3 cells and no dominant negative
e¡ect exerted by the exon 10-deleted ferrochelatase.
However, since there is a single amino acid di¡erence
between human and mouse exon 10, it is conceivable
that this di¡erence would prevent the proper dimer-
ization of the mutant and wild-type ferrochelatase
monomers, thus there would be no dominant nega-
tive e¡ect on the enzyme activity.
Our results suggest that, in addition to a mutation
that results in a null allele, a second mutation is
necessary to decrease expression of the ‘wild-type’
allele to produce the protoporphyric phenotype. Re-
cent reports of ferrochelatase levels in protoporphy-
ric patients show that in most cases not only are the
ferrochelatase activity levels less than 50%, but so are
the ferrochelatase protein levels [48]. It is possible
that a mutation in the ferrochelatase promoter could
decrease the expression of the wild-type allele. Evi-
dence of the heritability of a low expressing allele has
been shown in a family with protoporphyria [28].
A¡ected individuals possessed a mutant allele that
contained an exon 10 deletion, and a wild-type allele
that was low expressing. A single polymorphism has
been reported in the ferrochelatase promoter, an A
to G transition at 3251 (from the ATG codon)
which is not localized to any described cis-acting
elements [28]. We are currently investigating the ef-
fect of this polymorphism on ferrochelatase gene ex-
pression.
Alternatively, aberrant methylation of the CpG
island in the ferrochelatase promoter may decrease
the expression of the imprinted allele containing the
wild-type coding region. In the embryonic rho-globin
promoter, hyper-methylation of the 5P regulatory re-
gion results in developmentally regulated suppression
of erythroid gene transcription [49], and aberrant
methylation of CpG regions are implicated in a dis-
ease phenotype in other cases [50]. Studies on the
promoter for human O6-methylguanine DNA meth-
yltransferase gene show that precise nucleosome po-
sitioning, which is required for proper expression of
the gene, may be in£uenced by methylation of re-
gions of the CpG islands in the promoter [51]. In
this regard, we have shown that appropriate function
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of the ferrochelatase promoter requires a chromatin
environment [6]. It is tempting to speculate that in-
teraction between proximal and distal cis-elements in
the ferrochelatase promoter may be regulated by nu-
cleosome positioning, and perhaps parental imprint-
ing of the ‘wild-type’ allele in protoporphyric indi-
viduals results in aberrant nucleosome positioning
and a decrease in transcription from this allele.
We cannot discount the possibility that the di¡er-
ence in ferrochelatase activity observed in mouse
exon 10-deleted ES cells and human protoporphyric
cells may result from species di¡erences. Milder phe-
notypic expression in gene-targeted mouse models
for Duchenne muscular dystrophy [52], neuro¢bro-
matosis [53], metachromatic leukodystrophy [54],
and cystic ¢brosis [55] have been observed. The rea-
son for the less severe clinical sequela of these human
mutations in mice is not known. It is proposed that
the di¡erences may represent inadequate disruption
of the targeted gene, or that there may exist other
modulating factors present in humans, and not in
mice, that play a role in the phenotypic discordance.
In this study we utilized targeted ES cells grown in
culture outside the context of the whole organism.
An alternative hypothesis for the discrepancy in ac-
tivity between the human and mouse exon 10 dele-
tion mutation is that a prolonged exposure to ele-
vated protoporphyrin levels in a patient with
protoporphyria may decrease transcriptional or
translational expression of the wild-type ferrochela-
tase allele. It may be that during embryonic develop-
ment chronic exposure to elevated protoporphyrin
levels and/or anemia permanently alter the transcrip-
tion of genes that are directly, or indirectly, related
to ferrochelatase expression. We are currently inves-
tigating the e¡ect of this exon 10 deletion in hetero-
zygous mice. Because heme is an indispensable com-
ponent for many proteins, we predict that a
homozygous exon 10 deletion mutation in mice will
be lethal.
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